Lisa M DeAngelis

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma
    Gaurav D Shah
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4730-5. 2007
  2. ncbi request reprint Primary central nervous system lymphomas
    L M DeAngelis
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 6700, USA
    Curr Treat Options Oncol 2:309-18. 2001
  3. ncbi request reprint Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma
    Andreas F Hottinger
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Neurology 69:1178-82. 2007
  4. pmc Molecular interactions in the development of brain metastases
    Nina Martinez
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Int J Mol Sci 14:17157-67. 2013
  5. ncbi request reprint Carboxypeptidase G2 rescue after high-dose methotrexate
    L M DeAngelis
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 14:2145-9. 1996
  6. ncbi request reprint Treatment of primary central nervous system lymphoma
    Meltem Ekenel
    Lisa M DeAngelis, MD Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Treat Options Neurol 9:271-82. 2007
  7. ncbi request reprint Leptomeningeal metastasis
    Lisa M DeAngelis
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Invest 23:145-54. 2005
  8. ncbi request reprint Treatment of primary central nervous system lymphoma
    Lisa M DeAngelis
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 31:684-92. 2004
  9. ncbi request reprint Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10
    Lisa M DeAngelis
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:4643-8. 2002
  10. pmc High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 8:183-8. 2006

Research Grants

  1. Participating Member Institution in NABTC
    Lisa DeAngelis; Fiscal Year: 2007

Detail Information

Publications107 found, 100 shown here

  1. ncbi request reprint Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma
    Gaurav D Shah
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4730-5. 2007
    ....
  2. ncbi request reprint Primary central nervous system lymphomas
    L M DeAngelis
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 6700, USA
    Curr Treat Options Oncol 2:309-18. 2001
    ..Emerging data support the validity of this approach, and the development of more efficacious chemotherapeutic regimens has been the focus of recent research...
  3. ncbi request reprint Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma
    Andreas F Hottinger
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Neurology 69:1178-82. 2007
    ..Consequently, patients are often treated with chemotherapy alone, and WBRT is deferred until relapse...
  4. pmc Molecular interactions in the development of brain metastases
    Nina Martinez
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Int J Mol Sci 14:17157-67. 2013
    ..This review summarizes recent work focused on the molecular derangements leading to brain metastases and outlines areas in need of greater understanding. ..
  5. ncbi request reprint Carboxypeptidase G2 rescue after high-dose methotrexate
    L M DeAngelis
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 14:2145-9. 1996
    ..This study was a pilot project to assess the safety and efficacy of carboxypeptidase G2 (CPG2) rescue from high-dose (HD) methotrexate (MTX) in patients with recurrent cerebral lymphoma...
  6. ncbi request reprint Treatment of primary central nervous system lymphoma
    Meltem Ekenel
    Lisa M DeAngelis, MD Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Treat Options Neurol 9:271-82. 2007
    ..This review summarizes the literature regarding the treatment of PCNSL in immunocompetent patients...
  7. ncbi request reprint Leptomeningeal metastasis
    Lisa M DeAngelis
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Invest 23:145-54. 2005
    ..Nevertheless, some patients, particularly those with leukemia, lymphoma, and breast cancer, respond and a substantial minority will be alive one to two years after diagnosis...
  8. ncbi request reprint Treatment of primary central nervous system lymphoma
    Lisa M DeAngelis
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 31:684-92. 2004
    ..Consequently, the role of radiotherapy remains to be clarified in newly diagnosed younger patients with PCNSL...
  9. ncbi request reprint Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10
    Lisa M DeAngelis
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:4643-8. 2002
    ..Cranial irradiation alone rarely results in long-term disease control or prolonged survival. We prospectively studied the use of combination chemotherapy plus cranial irradiation in newly diagnosed patients with PCNSL...
  10. pmc High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 8:183-8. 2006
    ..This treatment strategy affords long-term disease control to a subset of patients with newly diagnosed anaplastic oligodendroglioma without evidence of delayed neurotoxicity or myelodysplasia...
  11. doi request reprint Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome
    Patrick G Morris
    Patrick G Morris, Denise D Correa, Joachim Yahalom, Anne S Reiner, Kathy Panageas, Sasan Karimi, Richard Curry, Gaurav Shah, Lauren E Abrey, Lisa M DeAngelis, and Antonio Omuro, Memorial Sloan Kettering Cancer Center Rose K Lai, Columbia University, New York, NY Jeffrey J Raizer and Sean Grimm, Northwestern University, Chicago, IL David Schiff, University of Virginia, Charlottesville, VA and Barbara Grant, University of Vermont, Burlington, VT
    J Clin Oncol 31:3971-9. 2013
    ....
  12. pmc Initial treatment patterns over time for anaplastic oligodendroglial tumors
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, 3rd Floor, New York, NY 10021, USA
    Neuro Oncol 14:761-7. 2012
    ..01), and frontal lobe predominance (P < .05). Limited level 1 evidence is currently available to guide treatment decisions, and ongoing phase III trials will be critical to understanding the optimal therapy...
  13. pmc Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
    Fabio M Iwamoto
    The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 13:1244-51. 2011
    ..4, P< .0001). Longitudinal increases in serum YKL-40 are associated with increased risk of death in patients with glioblastomas and anaplastic gliomas. YKL-40 is also a putative indicator of disease status in these patients...
  14. pmc A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
    Jeffrey J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Neuro Oncol 12:95-103. 2010
    ..001). Single-agent activity of erlotinib is minimal for recurrent MGs and marginally beneficial following RT for NP GBM patients. Development of rash in cycle 1 correlates with survival in patients with NP GBM after RT...
  15. ncbi request reprint Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study
    Rose Lai
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neurology 62:451-6. 2004
    ..Treatment-related leukoencephalopathy is the leading toxicity after successful treatment of primary CNS lymphoma (PCNSL). Its mechanism is poorly understood and there are no autopsy data available on such patients...
  16. pmc International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
    Andrew B Lassman
    Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Neuro Oncol 13:649-59. 2011
    ..Combined CT + RT led to longer disease control and survival than did CT or RT alone in cases with no 1p19q deletion. Ongoing trials will address these issues prospectively...
  17. doi request reprint Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy
    Meltem Ekenel
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 113:1025-31. 2008
    ..Therefore, a retrospective study was conducted to assess the impact of consolidation treatment after a CR to initial induction chemotherapy on disease control and survival...
  18. pmc Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Antonio Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 15:242-50. 2013
    ..In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)...
  19. doi request reprint Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas
    Fabio M Iwamoto
    The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Neurooncol 105:607-12. 2011
    ..Changes in serum MMP-9 were not associated with survival in the anaplastic glioma cohort. Serum MMP-9 showed no utility in determining glioma disease status and was not a clinically relevant prognostic marker of survival...
  20. pmc Cognitive functions in primary CNS lymphoma after single or combined modality regimens
    Denise D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 14:101-8. 2012
    ..Cognitive dysfunction was more prevalent in PCNSL survivors treated with WBRT + HD-MTX compared with patients treated with HD-MTX alone...
  21. doi request reprint YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma
    Andreas F Hottinger
    Brain Tumor Center, New York, NY, USA
    Ann Neurol 70:163-9. 2011
    ..To evaluate YKL-40 and MMP-9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL)...
  22. doi request reprint Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy
    Patrick G Morris
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 52:1891-7. 2011
    ..51). Similarly, there were no differences in response rates or overall survival according to MTX AUC, suggesting that intra-patient dose escalation to increase MTX exposure is unnecessary when our regimen is utilized...
  23. pmc Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma
    Jennifer L Clarke
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA
    J Clin Oncol 27:3861-7. 2009
    ..The goal of this randomized phase II study was to evaluate two different temozolomide regimens in the adjuvant treatment of newly diagnosed GBM...
  24. ncbi request reprint Patterns of treatment in older adults with primary central nervous system lymphoma
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 110:1338-44. 2007
    ..The objective of the current study was to identify factors associated with the receipt and type of treatment in a population-based cohort of older PCNSL patients...
  25. ncbi request reprint Longitudinal cognitive follow-up in low grade gliomas
    Denise D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Neurooncol 86:321-7. 2008
    ....
  26. doi request reprint Spectrum of nonconvulsive status epilepticus in patients with cancer
    Meredith Spindler
    Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, NY, USA
    J Clin Neurophysiol 30:339-43. 2013
    ..Determine incidence, clinical presentation, electrographic correlates, and outcome of nonconvulsive status epilepticus (NCSE) in cancer patients on whom an EEG was performed...
  27. doi request reprint Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma
    Lakshmi Nayak
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Leuk Lymphoma 54:58-61. 2013
    ..Given the overall modest activity, this regimen should be reserved for patients who are not candidates for other, more aggressive salvage treatments...
  28. pmc A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas
    Jeffrey J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Neuro Oncol 12:87-94. 2010
    ..This has important implications for further development of this drug in the treatment of MG as well as the optimal management of patients with other malignancies such as NSCLC who are on enzyme-inducing drugs...
  29. ncbi request reprint Delayed neurotoxicity in primary central nervous system lymphoma
    Antonio M P Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Neurol 62:1595-600. 2005
    ..This delayed neurotoxicity has been poorly defined in the literature, and the underlying mechanisms are unknown...
  30. doi request reprint Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience
    Douglas E Ney
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 116:4605-12. 2010
    ....
  31. ncbi request reprint Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up
    Antonio M P Omuro
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Neurology 64:69-74. 2005
    ..To assess the efficacy and safety of a preradiation chemotherapy regimen in patients with primary CNS lymphoma (PCNSL), with emphasis on long-term outcomes...
  32. doi request reprint Neurological outcome of long-term glioblastoma survivors
    Andreas F Hottinger
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Neurooncol 95:301-5. 2009
    ..7 years from diagnosis (range: 0.9-11.5 years). Long-term survivors remain rare, but are found across all age groups despite multiple recurrences; clinically significant delayed complications of treatment are common...
  33. doi request reprint Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy
    Patrick G Morris
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 7:382-5. 2012
    ..A retrospective review was carried out to assess the impact of whole brain radiotherapy (WBRT), intrathecal therapy (IT), and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) on outcomes...
  34. pmc Late relapse in primary central nervous system lymphoma: clonal persistence
    Lakshmi Nayak
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Neuro Oncol 13:525-9. 2011
    ..Long-term persistence of the PCNSL clone was observed in one patient. Patients with late relapses have a good response to salvage therapy and prolonged survival...
  35. ncbi request reprint Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: preliminary findings
    Denise Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Adv Hematol Oncol 1:490. 2003
  36. pmc Survey of treatment recommendations for anaplastic oligodendroglioma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 9:314-8. 2007
    ....
  37. ncbi request reprint Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma
    Igor T Gavrilovic
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:4570-4. 2006
    ..The purpose of this report is to update the initial results and provide long-term data regarding overall survival, patterns of relapse, and the risk of treatment-related neurotoxicity...
  38. pmc Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center
    Mary R Welch
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 14:1304-11. 2012
    ..Aggressive therapy should be offered to select patients irrespective of advanced age...
  39. ncbi request reprint Capecitabine therapy of central nervous system metastases from breast cancer
    Meltem Ekenel
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Neurooncol 85:223-7. 2007
    ..Capecitabine may achieve a CR and provide long-term control in patients with both leptomeningeal and parenchymal CNS metastases from breast cancer...
  40. doi request reprint Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy
    Denise D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Neurooncol 91:315-21. 2009
    ..There was no significant cognitive decline up to 24 months post-chemotherapy and reduced-dose WBRT in this group of PCNSL patients, however, difficulties in Verbal Memory and Motor speed persisted over the follow-up period...
  41. ncbi request reprint Cognitive functions in low-grade gliomas: disease and treatment effects
    Denise D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Neurooncol 81:175-84. 2007
    ..The few published studies examining adverse treatment effects on cognition revealed conflicting results...
  42. ncbi request reprint Bcl-6 predicts improved prognosis in primary central nervous system lymphoma
    Oren Levy
    Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York, USA
    Cancer 112:151-6. 2008
    ..The objectives of this study were to characterize the immunophenotypes of PCNSL samples and to determine their utility in predicting clinical outcomes...
  43. ncbi request reprint High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    J Neurooncol 65:127-34. 2003
    ....
  44. ncbi request reprint Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis
    Lauren E Abrey
    Departments of Neurology and Medicine and the Office of Clinical Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:4151-6. 2003
    ..To assess the safety and efficacy of intensive methotrexate-based chemotherapy followed by high-dose chemotherapy (HDT) with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma (PCNSL)...
  45. ncbi request reprint Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 11:7841-50. 2005
    ....
  46. doi request reprint Steroid management in newly diagnosed glioblastoma
    Mariel B Deutsch
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Neurooncol 113:111-6. 2013
    ..Steroids are often tapered during RT, but there is frequent taper failure with this approach. A prospective trial with standardized steroid dosing regimens would be needed to verify these findings...
  47. pmc Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors
    Lakshmi Nayak
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Neurology 80:1598-605; discussion 1603. 2013
    ..To evaluate the utility of rare cell capture technology (RCCT) in the diagnosis of leptomeningeal metastasis (LM) from solid tumors through identification of circulating tumor cells (CTCs) in the CSF...
  48. doi request reprint Herpes simplex encephalitis in patients with cancer
    Jerome J Graber
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Neurooncol 105:415-21. 2011
    ..MRI findings were typical, but CSF white blood cell count was normal in four patients and one had negative CSF testing, suggesting that CSF results may be misleading in this population...
  49. ncbi request reprint Ventriculoperitoneal shunt in patients with leptomeningeal metastasis
    Antonio M P Omuro
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neurology 64:1625-7. 2005
    ..Median overall survival was 2 months (range 2 days to 3.6 years) after VP shunt placement, but there was no procedure-related mortality. The prognosis of LM remained poor, but VP shunt can be an effective palliative tool when required...
  50. ncbi request reprint Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
    Raja B Khan
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Neurooncol 58:175-8. 2002
    ..Using a case-controlled retrospective study, matching patients treated with HD-MTX with or without IT-MTX, we found no difference in survival, disease control, or neurotoxicity...
  51. ncbi request reprint Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment
    Adilia Hormigo
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 126:202-8. 2004
    ..Patients whose ocular disease was identified and treated before CNS progression had a significantly improved survival...
  52. ncbi request reprint YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas
    Adilia Hormigo
    Clinical Laboratories, Neurosurgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Cancer Res 12:5698-704. 2006
    ..We obtained prospective longitudinal serum samples from patients with gliomas to determine whether YKL-40 or MMP-9 could be used as serum markers...
  53. doi request reprint Post-treatment T1 shortening in primary CNS lymphoma
    Sasan Karimi
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Neurooncol 111:25-31. 2013
    ..To assess the prognostic significance of this novel finding, additional studies focusing on disease recurrence and patient survival are warranted...
  54. ncbi request reprint Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5711-5. 2006
    ....
  55. ncbi request reprint Utility of brain FDG-PET in primary CNS lymphoma
    Nimish A Mohile
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Adv Hematol Oncol 6:818-20, 840. 2008
    ..This data suggests that FDG-PET imaging in PCNSL is useful and may have a role in response assessment...
  56. ncbi request reprint Retinopathy in survivors of primary central nervous system lymphoma
    Sean A Grimm
    Memorial Sloan Kettering Cancer Center, Department of Neurology, 1275 York Avenue, New York, NY 10021, USA
    Neurology 67:2060-2. 2006
    ..We describe five patients with long-term primary CNS lymphoma who were diagnosed with retinopathy several years after treatment with chemotherapy and WBRT...
  57. ncbi request reprint Necrotizing vasculopathy of the CNS: case report
    Martin Begemann
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA
    J Neurooncol 72:191-3. 2005
    ..Other organs such as liver, lung, and kidneys were spared. Necrotizing vasculopathy is a novel entity that should be considered in the differential diagnosis of PCNSL...
  58. pmc Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors
    Igor Vivanco
    Human Oncology and Pathogenesis Program, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Discov 2:458-71. 2012
    ....
  59. doi request reprint Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors
    Samuel A Goldlust
    Department of Neurology and the Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Neurooncol 107:407-11. 2012
    ..Prior exposure to VEGFR-TKIs may not preclude response to BEV, but sensitivity to BEV may be lower following more robust VEGFR inhibition...
  60. ncbi request reprint Treatment of primary central nervous system lymphoma
    Meltem Ekenel
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Neurol Neurosci Rep 7:191-9. 2007
    ..This review summarizes the literature regarding the treatment of PCNSL in immunocompetent patients...
  61. doi request reprint Ischemic stroke in patients with primary brain tumors
    Teri N Kreisl
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neurology 70:2314-20. 2008
    ..Primary brain tumor patients are at increased risk for stroke from disease and treatment-specific mechanisms...
  62. ncbi request reprint Intratumoral hemorrhage after thrombolysis in a patient with glioblastoma multiforme
    Sean A Grimm
    New York, NY 10021, USA
    Neurology 69:936. 2007
  63. ncbi request reprint Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:2466-72. 2005
    ..The objective of this study was to examine time trends in overall survival and disease-specific mortality in a population-based cohort of patients with PCNSL...
  64. ncbi request reprint Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma
    J J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Abbott Hall, Room 1123, 710 North Lake Shore Drive, Chicago, IL 60611, USA
    J Neurooncol 71:173-80. 2005
    ..Patients often have complete responses but relapses are common. We characterized the MR spectra of PCNSL patients, correlated MRSI with MRI and evaluated whether early recurrence could be detected by MRSI...
  65. doi request reprint Use of recombinant tissue plasminogen activator in cancer patients with acute stroke
    Jerome J Graber
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Neurooncol 107:571-3. 2012
    ..Only one of our six patients suffered minor bleeding as a complication of rTPA. Acute stroke in patients with cancer may be treated with rTPA, and active cancer should not be considered an absolute contraindication to rTPA use...
  66. ncbi request reprint Treatment of brain metastases
    Teri Nguyen
    Department of Neurology, Weill Medical College of Cornell University, New York, New York, USA
    J Support Oncol 2:405-10; discussion 411-6. 2004
    ..Patients with recurrent brain metastases can also benefit from additional treatment, including all the modalities available at diagnosis...
  67. ncbi request reprint Primary ocular lymphoma: clinical features, diagnosis, and treatment
    Adilia Hormigo
    Department of Neurology, New York Presbyterian Hospital and Weill College of Medicine of Cornell University, New York, USA
    Clin Lymphoma 4:22-9. 2003
    ..The current treatment options are discussed. Although advances have been made, the optimal treatment for primary ocular lymphoma remains to be identified..
  68. ncbi request reprint Benefits of adjuvant chemotherapy in high-grade gliomas
    Lisa M DeAngelis
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Semin Oncol 30:15-8. 2003
    ....
  69. ncbi request reprint An update on primary central nervous system lymphoma
    Fabio M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 20:1267-85. 2006
    ..However, the optical treatment approach is still unclear and therapy can be associated with long-term neurotoxicity. Current research focuses on maximizing survival while minimizing neurologic sequelae...
  70. doi request reprint Therapy of chemotherapy-induced peripheral neuropathy
    Thomas J Kaley
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Br J Haematol 145:3-14. 2009
    ..Unfortunately, even when effective in other types of neuropathic pain, anti-depressants and anticonvulsants have not yet proven effective for treating the symptoms of CIPN...
  71. ncbi request reprint Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:5034-43. 2005
    ..We hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow us to develop better therapies for patients...
  72. ncbi request reprint Neurologic complications of cancer chemotherapy
    Joohee K Sul
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 33:324-32. 2006
    ..This review will discuss the common complications of both established and novel agents used to treat cancer...
  73. pmc The utility of body FDG PET in staging primary central nervous system lymphoma
    Nimish A Mohile
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Neuro Oncol 10:223-8. 2008
    ..Body FDG PET may be an important noninvasive adjunct to conventional PCNSL staging, and its utility should be evaluated prospectively...
  74. ncbi request reprint Treatment for primary CNS lymphoma: the next step
    L E Abrey
    Departments of Neurology and Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 18:3144-50. 2000
    ..The reported protocol was designed to optimize and enhance the chemotherapeutic component of treatment...
  75. ncbi request reprint Brain abscesses in children with cancer
    N L Antunes
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Med Pediatr Oncol 31:19-21. 1998
    ..We reviewed the records of children who developed a brain abscess during treatment of a malignancy to define the clinical characteristics, prognosis, and management of these patients...
  76. ncbi request reprint Cognitive functions in survivors of primary central nervous system lymphoma
    D D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Neurology 62:548-55. 2004
    ..This combined regimen prolongs patient survival, but also carries a substantial risk for delayed neurotoxicity particularly in the elderly. However, cognitive outcome evaluations have not been included in most clinical trials...
  77. ncbi request reprint An integrated functional magnetic resonance imaging procedure for preoperative mapping of cortical areas associated with tactile, motor, language, and visual functions
    J Hirsch
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Neurosurgery 47:711-21; discussion 721-2. 2000
    ..To evaluate an integrated battery of preoperative functional magnetic resonance imaging (fMRI) tasks developed to identify cortical areas associated with tactile, motor, language, and visual functions...
  78. ncbi request reprint Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients
    Fabio M Iwamoto
    Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, NY, USA
    Neurology 66:1763-5. 2006
    ..All patients underwent radiation therapy, and three received chemotherapy. Complete response was achieved in 100% of patients, but three developed systemic relapse...
  79. ncbi request reprint Brain metastases
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Neurol Clin 21:1-23, vii. 2003
    ..This article reviews the epidemiology, clinical features, treatment, and prognosis of brain metastases from system malignancies...
  80. ncbi request reprint Brain metastases
    Teri D Nguyen
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Neurol Clin 25:1173-92, x-xi. 2007
    ..While better definitive strategies are investigated, physicians must remember to optimize the use of supportive therapies to ameliorate symptoms and maintain quality of life...
  81. ncbi request reprint Nonconvulsive status epilepticus in patients with cancer: imaging abnormalities
    Adilia Hormigo
    Department of Neurology, Memorial Sloan Kettering Cancer Center, and Weill Medical College of Cornell University, New York, NY 10021, USA
    Arch Neurol 61:362-5. 2004
    ..Convulsive status epilepticus may cause reversible neuroimaging abnormalities. These cortical changes have been reported rarely in association with nonconvulsive status epilepticus...
  82. ncbi request reprint Primary central nervous system T-cell lymphoma
    J M Gijtenbeek
    Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Neurology 57:716-8. 2001
    ..The prognosis of T-cell PCNSL may be worse than that of comparable B-cell tumors...
  83. ncbi request reprint High-grade gliomas in patients with prior systemic malignancies
    Fernando C Maluf
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 94:3219-24. 2002
    ..The current study was conducted to characterize the impact of a prior malignancy on the diagnosis, treatment, and outcome of high-grade glioma...
  84. ncbi request reprint Primary CNS lymphoma: a whole-brain disease?
    Rose Lai
    Departments of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neurology 59:1557-62. 2002
    ..Autopsy studies reveal that most primary CNS lymphomas (PCNSL) extensively infiltrate the brain. To date, there has been no correlation of autopsy findings with a modern neuroimaging assessment of tumor burden...
  85. ncbi request reprint Nervous system neoplasms
    Martin Goldstein
    Department of Neurology, New York Hospital Cornell Medical Center, New York, New York, USA
    Adv Neurol 90:157-73. 2002
  86. ncbi request reprint Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells
    Bin Gu
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Anticancer Drugs 16:167-74. 2005
    ..Combining inducers of DTD and cytochrome b5 reductase with bioreductive agents may be a potential therapeutic strategy for glioblastoma...
  87. pmc Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
    F M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Neurology 73:1200-6. 2009
    ..However, patterns of relapse, prognosis, and outcome of further therapy after bevacizumab failure have not been studied systematically...
  88. ncbi request reprint Stroke in patients with cancer: incidence and etiology
    D M Cestari
    Department of Neurology, Weill College of Medicine of Cornell University, New York, USA
    Neurology 62:2025-30. 2004
    ..To assess the incidence and type of strokes in patients with cancer at Memorial Sloan-Kettering Cancer Center...
  89. ncbi request reprint Multifocal strokes as the presentation of occult lung cancer
    Babak B Navi
    Weill Cornell Medical Center, New York, NY, USA
    J Neurooncol 85:307-9. 2007
    ..Our patient had a rapidly deteriorating course with recurrent strokes despite numerous anti-platelet and anti-coagulant agents, and was only responsive to chemotherapy aimed at the underlying cancer...
  90. ncbi request reprint Treatment of primary central nervous system lymphoma
    Gaurav D Shah
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 19:611-27, v. 2005
    ..In this article, the authors review the standard treatment for upfront and recurrent PCNSL...
  91. ncbi request reprint Neurologic complications of leukemia
    Alexis Demopoulos
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Neurol 15:691-9. 2002
    ..Recognizing and rapidly treating metastatic complications or avoiding neurotoxic therapies improves outcome, reduces morbidity and mortality, and limits long-term sequelae...
  92. pmc Bevacizumab for recurrent ependymoma
    R M Green
    Department of Neurology, Kaiser Permanente, Los Angeles Medical Center, Los Angeles, USA
    Neurology 73:1677-80. 2009
    ..At recurrence, ependymoma is notoriously refractory to therapy and the prognosis is poor. In recurrent glioblastoma, encouraging responses with bevacizumab have been observed...
  93. pmc Leptomeningeal metastases in the MRI era
    J L Clarke
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neurology 74:1449-54. 2010
    ..The diagnostic gold standard has been CSF cytology, but MRI is now used routinely for diagnosis. Diagnosis and prognosis of LM has not been studied in the MRI era...
  94. pmc Intracerebral and subarachnoid hemorrhage in patients with cancer
    B B Navi
    Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, NY, USA
    Neurology 74:494-501. 2010
    ..To analyze the risk factors, presentation, etiologies, and outcomes of adult cancer patients with intracranial hemorrhage (IH)...
  95. pmc Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas
    Kathleen R Lamborn
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, UC Clinics 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 10:162-70. 2008
    ..Earlier assessments of progression status also predicted survival and may be incorporated in the design of future clinical trials...
  96. ncbi request reprint Primary central nervous system lymphoma: a curable brain tumor
    Lisa M DeAngelis
    J Clin Oncol 21:4471-3. 2003
  97. ncbi request reprint Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
    Timothy F Cloughesy
    UCLA Neuro Oncology Program, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA 90095, USA
    J Clin Oncol 24:3651-6. 2006
    ..Because tipifarnib undergoes extensive hepatic metabolism, MTD is doubled in patients on EIAEDs. The population included 67 patients with glioblastoma multiforme (GBM) and an exploratory group of 22 patients with anaplastic glioma (AG)...
  98. ncbi request reprint Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
    Patrick Y Wen
    Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 12:4899-907. 2006
    ..Phase II: To determine the therapeutic efficacy of imatinib...
  99. ncbi request reprint Central nervous system cancers: Clinical Practice Guidelines in Oncology
    Steven S Brem
    J Natl Compr Canc Netw 3:644-90. 2005
  100. ncbi request reprint Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide
    Roelien H Enting
    Department of Neurology, University Hospital, Groningen, The Netherlands
    Neurology 63:901-3. 2004
    ..7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL...
  101. ncbi request reprint Chemotherapy for low-grade gliomas: emerging consensus on its benefits
    Patrick Y Wen
    Neurology 68:1762-3. 2007

Research Grants2

  1. Participating Member Institution in NABTC
    Lisa DeAngelis; Fiscal Year: 2007
    ..abstract_text> ..